Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 vs triamcinolone for acute gout in NSAID/colchicine-intolerant patients
CTR20131300Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in gout, sponsored by Novartis. Started Aug 2014; status: terminated.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on CTR20131300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131300.